People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Abata Therapeutics, Inc. | — | Biotechnology | Series C | $60.3M | $168.5M | 2023 |
ELLEN CAHIR-MCFARLAND at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ELLEN CAHIR-MCFARLAND on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Shelley Chu | 1 | 10 |
| David Kaufman | 1 | 7 |
| ABBIE CELNIKER | 1 | 6 |
| Lorence Kim | 1 | 5 |
| Nagesh Mahanthappa | 1 | 2 |
| SAMANTHA SINGER | 1 | 2 |
| Mitch Finer | 1 | 2 |
| VALERIE ODEGARD | 1 | 1 |
| STEPHEN SOFEN | 1 | 1 |
| SANDY LAZZARI | 1 | 1 |
| JOHN TRZUPEK | 1 | 1 |
| LEONARD DRAGONE | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.